Locus Biosciences INC
UEI CJKVLKZGX6F3 · NC · SAM.gov record ↗
$32.8M
FY2025 obligations
2
Contract awards
Sep 27, 2020
First action
May 10, 2026
Latest action
Obligations by agency
- Department Of Health And Human Services$32.8M
Obligations by NAICS
Monthly obligations
Feb 25
Sep 25
Feb 26
May 26
Contracts ending within 18 months (recompete watch)
- 75A50120C00169 ↗$24.9M
THE PURPOSE OF THIS BILATERAL MODIFICATION IS TO: 1.SUPPLEMENTALLY FUND CLIN 0003. 2.UPDATE KEY PERSONNEL. 3.EXTEND PERIOD OF PERFORMANCE FOR CLINS 0002 AND 0003 TO END 12/31/2026.
- Ends
- Dec 30, 2026
- Started
- Sep 27, 2020
- Agency
- Office Of Assistant Secretary For Preparedness And Response
- NAICS
- 541714
| PIID | Description | Agency | NAICS | Obligated | Start | End |
|---|---|---|---|---|---|---|
| 75A50120C00169 ↗ | THE PURPOSE OF THIS BILATERAL MODIFICATION IS TO: 1.SUPPLEMENTALLY FUND CLIN 0003. 2.UPDATE KEY PERSONNEL. 3.EXTEND PERIOD OF PERFORMANCE FOR CLINS 0002 AND 0003 TO END 12/31/2026. | Office Of Assistant Secretary For Preparedness And Response | 541714 | $24.9M | Sep 27, 2020 | Dec 30, 2026 |
Largest awards
- 75A50120C00169 ↗$24.9M
THE PURPOSE OF THIS BILATERAL MODIFICATION IS TO: 1.SUPPLEMENTALLY FUND CLIN 0003. 2.UPDATE KEY PERSONNEL. 3.EXTEND PERIOD OF PERFORMANCE FOR CLINS 0002 AND 0003 TO END 12/31/2026.
- Ends
- Dec 30, 2026
- Started
- Sep 27, 2020
- Agency
- Office Of Assistant Secretary For Preparedness And Response
- NAICS
- 541714
- 75N93025C00035 ↗$7.9M
ADVANCE A NOVEL THERAPEUTIC TO A FIRST-IN-HUMAN CLINICAL STUDY
- Ends
- Feb 6, 2029
- Started
- Sep 23, 2025
- Agency
- National Institutes Of Health
- NAICS
- 541714
| PIID | Description | Agency | NAICS | Obligated | Start | End |
|---|---|---|---|---|---|---|
| 75A50120C00169 ↗ | THE PURPOSE OF THIS BILATERAL MODIFICATION IS TO: 1.SUPPLEMENTALLY FUND CLIN 0003. 2.UPDATE KEY PERSONNEL. 3.EXTEND PERIOD OF PERFORMANCE FOR CLINS 0002 AND 0003 TO END 12/31/2026. | Office Of Assistant Secretary For Preparedness And Response | 541714 | $24.9M | Sep 27, 2020 | Dec 30, 2026 |
| 75N93025C00035 ↗ | ADVANCE A NOVEL THERAPEUTIC TO A FIRST-IN-HUMAN CLINICAL STUDY | National Institutes Of Health | 541714 | $7.9M | Sep 23, 2025 | Feb 6, 2029 |